Prognosis of PCI in AMI setting in the elderly population: Outcomes from the multicenter prospective e-ULTIMASTER registry.
age
coronary artery disease
elderly
myocardial infarction
outcome
stent
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
03
07
2022
received:
05
02
2022
accepted:
12
07
2022
pubmed:
9
9
2022
medline:
16
12
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
Elderly patients with ST-elevation myocardial infarction (STEMI) who undergo percutaneous coronary intervention (PCI) are usually excluded from major trials. This study sought to assess 1-year clinical outcomes following PCI with a drug-eluting stent in patients older than 80 years old with STEMI. The large all-comer, multicontinental e-ULTIMASTER registry included 7507 patients with STEMI who underwent PCI using the Ultimaster stent. The primary clinical endpoint was 1-year target lesion failure, a composite of cardiac death (CD), target vessel-related myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR). There were 457 (6.1%) patients in the elderly group (≥80 years old) that were compared to 7050 (93.9%) patients <80 years. The elderly patients included more female patients and had significantly more comorbidities and had more complex coronary anatomy. The primary endpoint occurred in 7.2% of the elderly, compared to 3.1% of the younger group (p < .001). All-cause mortality was significantly higher among the elderly group compared to the younger group (10.1% vs. 2.3%, p < .0001), as well as CD (6.1% vs. 1.6%, p < .0001), but not TV-MI (1.1% vs. 0.7%, p = .34) or CD-TLR (1.1% vs. 1.4%, p = .63). Elderly patients with STEMI presentation had a higher incidence of the composite endpoint than younger patients. All-cause and CD were higher for elderly patients compared to patients younger than 80 years old. However, there was no difference in the incidence of TV-MI or target lesion revascularizations. These findings suggest that PCI for STEMI in elderly patients is relatively safe.
Sections du résumé
BACKGROUND
BACKGROUND
Elderly patients with ST-elevation myocardial infarction (STEMI) who undergo percutaneous coronary intervention (PCI) are usually excluded from major trials.
HYOPTHESIS
UNASSIGNED
This study sought to assess 1-year clinical outcomes following PCI with a drug-eluting stent in patients older than 80 years old with STEMI.
METHODS
METHODS
The large all-comer, multicontinental e-ULTIMASTER registry included 7507 patients with STEMI who underwent PCI using the Ultimaster stent. The primary clinical endpoint was 1-year target lesion failure, a composite of cardiac death (CD), target vessel-related myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR).
RESULTS
RESULTS
There were 457 (6.1%) patients in the elderly group (≥80 years old) that were compared to 7050 (93.9%) patients <80 years. The elderly patients included more female patients and had significantly more comorbidities and had more complex coronary anatomy. The primary endpoint occurred in 7.2% of the elderly, compared to 3.1% of the younger group (p < .001). All-cause mortality was significantly higher among the elderly group compared to the younger group (10.1% vs. 2.3%, p < .0001), as well as CD (6.1% vs. 1.6%, p < .0001), but not TV-MI (1.1% vs. 0.7%, p = .34) or CD-TLR (1.1% vs. 1.4%, p = .63).
CONCLUSION
CONCLUSIONS
Elderly patients with STEMI presentation had a higher incidence of the composite endpoint than younger patients. All-cause and CD were higher for elderly patients compared to patients younger than 80 years old. However, there was no difference in the incidence of TV-MI or target lesion revascularizations. These findings suggest that PCI for STEMI in elderly patients is relatively safe.
Identifiants
pubmed: 36072999
doi: 10.1002/clc.23902
pmc: PMC9748751
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1211-1219Subventions
Organisme : Terumo Europe N.V.
Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Références
Eur Heart J. 2014 Jun 14;35(23):1551-8
pubmed: 24644310
Circ J. 2013;77(1):89-95
pubmed: 23018634
Geriatr Gerontol Int. 2013 Jan;13(1):146-51
pubmed: 22672349
Angiology. 2017 Sep;68(8):688-697
pubmed: 27856669
J Am Coll Cardiol. 2013 Mar 19;61(11):1207-8
pubmed: 23375924
J Am Heart Assoc. 2019 Dec 3;8(23):e013786
pubmed: 31787055
Am Heart J. 2020 Oct;228:109-115
pubmed: 32882569
JACC Cardiovasc Interv. 2017 Jul 10;10(13):1295-1303
pubmed: 28683935
J Clin Med. 2021 Sep 14;10(18):
pubmed: 34575243
Cardiovasc Revasc Med. 2018 Jan;19(1 Pt A):12-16
pubmed: 28600019
Eur Heart J. 2022 Apr 19;43(16):1542-1553
pubmed: 34347065
Clin Cardiol. 2022 Dec;45(12):1211-1219
pubmed: 36072999
Clin Cardiol. 2009 Dec;32(12):E16-21
pubmed: 20014200
Open Heart. 2020 Aug;7(2):
pubmed: 32747454
Am J Med. 2019 Feb;132(2):209-216
pubmed: 30447205
Lancet. 2018 Jan 6;391(10115):41-50
pubmed: 29102362
Lancet. 2016 Mar 12;387(10023):1057-1065
pubmed: 26794722
J Am Coll Cardiol. 2007 May 1;49(17):1790-7
pubmed: 17466230
Eur Heart J. 2016 Apr 21;37(16):1304-11
pubmed: 26757786
J Am Coll Cardiol. 2014 Apr 15;63(14):1371-5
pubmed: 24216285
Am J Cardiol. 2000 Feb 1;85(3):338-43
pubmed: 11078303
Arch Intern Med. 2011 Mar 28;171(6):557-8
pubmed: 21444845
J Geriatr Cardiol. 2013 Mar;10(1):82-90
pubmed: 23610578
Cureus. 2020 Jul 23;12(7):e9349
pubmed: 32742886
J Am Heart Assoc. 2019 Mar 5;8(5):e011183
pubmed: 30791799
Am J Cardiol. 1999 Aug 1;84(3):245-51
pubmed: 10496430
Korean J Intern Med. 2015 Nov;30(6):821-8
pubmed: 26552457
Int J Cardiol. 2017 Sep 15;243:110-115
pubmed: 28579168
Am J Med. 2017 May;130(5):555-563
pubmed: 28065766